DIAMEDICA THERAPEUTICS INC (DMAC) Stock Price, Quote, News and Overview
NASDAQ:DMAC - Nasdaq - CA25253X2077 - Common Stock - Currency: USD
DMAC Quote, Performance and Key Statistics
4.17
+0.06 (+1.46%)
The current stock price of DMAC is 4.17 USD. In the past month the price decreased by -1.42%. In the past year, price increased by 62.89%.
DMAC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.21 | 330.30B | ||
| AMGN | AMGEN INC | 13.9 | 155.11B | ||
| GILD | GILEAD SCIENCES INC | 14.07 | 135.48B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.08 | 52.99B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.91B | ||
| ARGX | ARGENX SE - ADR | 101.67 | 35.70B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.19B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.3 | 26.59B | ||
| NTRA | NATERA INC | N/A | 21.94B | ||
| BIIB | BIOGEN INC | 8.29 | 19.22B | ||
| UTHR | UNITED THERAPEUTICS CORP | 12.99 | 14.68B |
Related stock screener links
About DMAC
Company Profile
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 27 full-time employees. The company went IPO on 2008-01-04. The firm is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. The company has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.
Company Info
DIAMEDICA THERAPEUTICS INC
301 Carlson Parkway, Suite 210
Minneapolis MINNESOTA 55447 US
CEO: Rick Pauls
Employees: 28
Phone: 17634965454
DIAMEDICA THERAPEUTICS INC / DMAC FAQ
What is the stock price of DIAMEDICA THERAPEUTICS INC today?
The current stock price of DMAC is 4.17 USD. The price increased by 1.46% in the last trading session.
What is the ticker symbol for DIAMEDICA THERAPEUTICS INC stock?
The exchange symbol of DIAMEDICA THERAPEUTICS INC is DMAC and it is listed on the Nasdaq exchange.
On which exchange is DMAC stock listed?
DMAC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DIAMEDICA THERAPEUTICS INC stock?
10 analysts have analysed DMAC and the average price target is 10.71 USD. This implies a price increase of 156.83% is expected in the next year compared to the current price of 4.17. Check the DIAMEDICA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DIAMEDICA THERAPEUTICS INC worth?
DIAMEDICA THERAPEUTICS INC (DMAC) has a market capitalization of 178.81M USD. This makes DMAC a Micro Cap stock.
How many employees does DIAMEDICA THERAPEUTICS INC have?
DIAMEDICA THERAPEUTICS INC (DMAC) currently has 28 employees.
What are the support and resistance levels for DIAMEDICA THERAPEUTICS INC (DMAC) stock?
DIAMEDICA THERAPEUTICS INC (DMAC) has a support level at 3.85 and a resistance level at 4.24. Check the full technical report for a detailed analysis of DMAC support and resistance levels.
Should I buy DIAMEDICA THERAPEUTICS INC (DMAC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DMAC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DMAC, evaluating the profitability, health, valuation and growth aspects
- DIAMEDICA THERAPEUTICS INC (DMAC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DIAMEDICA THERAPEUTICS INC (DMAC) Sales and EPS estimates to see what analysts future expectations are.
- DIAMEDICA THERAPEUTICS INC (DMAC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DIAMEDICA THERAPEUTICS INC (DMAC) Insider and Institutional Ownership to learn about the owners and their transactions.
- DIAMEDICA THERAPEUTICS INC (DMAC) Stock Chart to make your own analysis
- DIAMEDICA THERAPEUTICS INC (DMAC) Latest news and press-releases to stay up to date.
Does DIAMEDICA THERAPEUTICS INC (DMAC) stock pay dividends?
DMAC does not pay a dividend.
When does DIAMEDICA THERAPEUTICS INC (DMAC) report earnings?
DIAMEDICA THERAPEUTICS INC (DMAC) will report earnings on 2025-08-05, after the market close.
What is the Price/Earnings (PE) ratio of DIAMEDICA THERAPEUTICS INC (DMAC)?
DIAMEDICA THERAPEUTICS INC (DMAC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.64).
What is the Short Interest ratio of DIAMEDICA THERAPEUTICS INC (DMAC) stock?
The outstanding short interest for DIAMEDICA THERAPEUTICS INC (DMAC) is 2.8% of its float. Check the ownership tab for more information on the DMAC short interest.
DMAC Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to DMAC. When comparing the yearly performance of all stocks, DMAC is one of the better performing stocks in the market, outperforming 85.17% of all stocks.
DMAC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DMAC. The financial health of DMAC is average, but there are quite some concerns on its profitability.
DMAC Financial Highlights
Over the last trailing twelve months DMAC reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS decreased by -14.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.53% | ||
| ROE | -79.52% | ||
| Debt/Equity | 0 |
DMAC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to DMAC. The Buy consensus is the average rating of analysts ratings from 10 analysts.